KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Net Income (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Net Income data on record, last reported at -$35.0 million in Q3 2025.

  • For Q3 2025, Net Income rose 5.58% year-over-year to -$35.0 million; the TTM value through Sep 2025 reached -$113.4 million, up 32.19%, while the annual FY2024 figure was -$119.0 million, 56.73% up from the prior year.
  • Net Income reached -$35.0 million in Q3 2025 per NKTR's latest filing, up from -$39.2 million in the prior quarter.
  • Across five years, Net Income topped out at $7.3 million in Q4 2024 and bottomed at -$159.1 million in Q2 2022.
  • Average Net Income over 5 years is -$74.5 million, with a median of -$52.4 million recorded in 2024.
  • Peak YoY movement for Net Income: tumbled 56.9% in 2021, then skyrocketed 117.7% in 2024.
  • A 5-year view of Net Income shows it stood at -$146.8 million in 2021, then surged by 54.63% to -$66.6 million in 2022, then soared by 38.5% to -$41.0 million in 2023, then soared by 117.7% to $7.3 million in 2024, then plummeted by 582.53% to -$35.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$35.0 million in Q3 2025, -$39.2 million in Q2 2025, and -$46.4 million in Q1 2025.